Əsas səhifə

Çap

Əks əlaqə

İnfo
Progestogens and other hormone therapies in women with breast cancer and bone metastasis

Mündəricat

Progestogens and other hormone therapies in women with breast cancer and bone metastasis

Sübutlu məlumatların xülasələri
25.04.2018 • Sonuncu dəyişiklik 25.04.2018
Editors

Medroxyprogesterone acetate appears to be superior to tamoxifen in breast cancer patients with bone metastasis for global response rates, but there is insufficient evidence of improved survival.

A systematic review including 10 studies with a total of 562 subjects was abstracted in DARE. Results from all four studies comparing medroxyprogesterone acetate with tamoxifen showed a statistically significant difference in global response rates in favour of medroxyprogesterone acetate. No statistically significant differences between groups were found in three studies comparing megestrol acetate with tamoxifen. One study demonstrated a statistically significant effect of medroxyprogesterone acetate as compared to megestrol acetate.

Ədəbiyyat

  1. Leriche N, Bonneterre J. [Progestational agents and bone metastasis in breast cancer] Bull Cancer 1997 Sep;84(9):891-4.